Literature DB >> 17727318

High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction.

Elif Elmas1, Siegfried Lang, Carl Erik Dempfle, Thorsten Kälsch, Dieter Hannak, Tim Sueselbeck, Christian Wolpert, Martin Borggrefe, Martina Brueckmann.   

Abstract

BACKGROUND: Atherosclerotic plaques prone to cause thrombotic complications and plaque rupture account for the majority of fatal myocardial infarctions (MI), which may be complicated by ventricular fibrillation (VF). Matrix-degrading metalloproteinases (MMPs) and their inhibitors (TIMPs) are expressed in atherosclerotic lesions and contribute to plaque vulnerability. Interleukin-8 (IL-8) is one of the predominant chemokines interacting with MMPs and TIMPs and the coagulation system. The aim of the present study was to assess potential differences of levels of MMP-9, TIMP-1 and IL-8 in postmyocardial infarction patients with or without VF complicating acute MI.
METHODS: Blood samples were taken from 45 patients with VF complicating acute MI and from 88 patients without VF. All samples were collected during a symptom-free interval remote from the acute ischemic event with a median of 556 days. The markers of interest were TIMP-1, MMP-9 and IL-8.
RESULTS: IL-8 and TIMP-1 levels were significantly higher among patients with VF than among patients without VF (p<0.001). In a logistic regression approach IL-8 was an independent indicator of patients prone to VF during MI (p=0.03). High levels of TIMP-1 (p=0.05), MMP-9 (p=0.03), the MMP-9/TIMP-1 ratio (p=0.049) and hypertension (p=0.02) were found to be indicators in patients with reinfarction or unstable angina pectoris during follow-up. Hypertension (p=0.02) and MMP-9 (p=0.03) were the only significant indicators characterizing patients undergoing coronary reinterventions, such as percutaneous coronary interventions and coronary bypass surgery.
CONCLUSIONS: Higher TIMP-1 and IL-8 levels are present in patients with VF complicating MI. High TIMP-levels may be related to the degree of fibrosis which is a substrate for electrical instability and may contribute to the occurrence of VF. Patients prone to develop VF during MI seem to have an increased proinflammatory condition compared to patients without VF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17727318     DOI: 10.1515/CCLM.2007.286

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy.

Authors:  Elif Elmas; Christina Doesch; Stephan Fluechter; Miriam Freundt; Christel Weiss; Siegfried Lang; Thorsten Kälsch; Dariush Haghi; Jana Papassotiriou; Jan Kunde; Stefan O Schoenberg; Martin Borggrefe; Theano Papavassiliu
Journal:  Int J Cardiovasc Imaging       Date:  2010-09-26       Impact factor: 2.357

2.  Matrix metalloproteinase therapy in heart failure.

Authors:  Francis G Spinale; Nikole M Wilbur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

3.  Endothelin-1 is not predictive of ventricular ectopy or ventricular fibrillation during acute myocardial ischemia.

Authors:  Atman P Shah; James T Niemann; Scott Youngquist; Gary Josephson; John P Rosborough
Journal:  J Interferon Cytokine Res       Date:  2008-11       Impact factor: 2.607

Review 4.  Chemokines and Heart Disease: A Network Connecting Cardiovascular Biology to Immune and Autonomic Nervous Systems.

Authors:  Veronica Dusi; Alice Ghidoni; Alice Ravera; Gaetano M De Ferrari; Laura Calvillo
Journal:  Mediators Inflamm       Date:  2016-05-03       Impact factor: 4.711

5.  Inflammatory plasma proteins predict short-term mortality in patients with an acute myocardial infarction.

Authors:  T Schmitz; E Harmel; M Heier; A Peters; J Linseisen; C Meisinger
Journal:  J Transl Med       Date:  2022-10-08       Impact factor: 8.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.